The nature of asthma as a chronic, persistent inflammatory disease of the airways has led to the development and widespread use of inhaled steroids, which are currently considered to be the most effective and safe drugs for the chronic treatment of asthma. However, in patients with moderate to severe asthma, adequate control of their asthma, particularly nocturnal symptoms, may not be achieved even with high doses (over 1000,~g per day) of 0954-6111/99/010033+06 $12.00/o 34 B. WALLAERT ET AL.
inhaled steroids. According to recent recommendations (l), concomitant treatment with long-acting bronchodilators should be considered for those patients and these drugs may be given by the oral or inhaled route. Although it is recognized that there are advantages in using the inhaled route for asthma therapies, there are many patients who do not obtain maximum benefit from this type of therapy because they cannot use their inhalers efficiently, often despite repeated instruction (2). In those and other patients who prefer to take tablets, oral medication is preferable. Bambuterol and salmeterol are long-acting bronchodilators which have been developed for oral and inhaled therapy, respectively. Bambuterol is a once-daily oral /&-agonist. It is a pharmacologically inactive prodrug of terbutaline, which has a high pre-systemic and hydrolytic stability (3). Following slow absorption from the gastrointestinal tract, it is converted into the active metabolite (45). Clinical studies have shown that bambuterol, 10 and 20 mg, administered once daily, has a good bronchodilating effect over 24 h (6) and is associated with less tremor than controlled release preparations of salbutamol (7) or terbutaline (8).
Maximum serum levels after late evening administration are achieved during the night or early morning (6), giving the drug an ideal pharmacokinetic profile for the treatment of nocturnal asthma symptoms (9). Salmeterol is a longacting inhaled /&-agonist with a bronchodilator effect that lasts for up to 12 h (10) and it has also been shown to be effective for treatment of nocturnal asthma in a dose of 50 pg b.i.
d. (11).
The primary objective of this study was to compare the efficacy of bambuterol and salmeterol in chronic, moderate to severe asthmatic patients experiencing nocturnal asthma symptoms, despite what we considered to be optimal antiinflammatory treatment with inhaled steroids. This study represents the first large controlled comparison of these two drugs in patients of this severity.
PATIENTS AND METHODS

Patients
Patients with moderate to severe asthma, as defined in the International Consensus Report (l), were recruited for study if they fulfilled the following major inclusion criteria. 1. Men and women aged 18-70 years being treated with a constant daily dose of inhaled andlor oral corticosteroids (800-2OOOpg day-' of budesonide, flunisolide, or beclomethasone via MD1 or 400-2OOOpg day -' budesonide via Turbuhaler@ (Astro Draco, Lund, Sweden) and/or oral prednisolone up to 20 mg day-' or equivalent), during the month prior to study. 2. Nocturnal awakening or early awakening due to asthma symptoms which required rescue medication at least once during a 2-week run-in period. 3. 2 15% fall in overnight PEF during 3 out of the last 7 days of run-in. 4. FEV, to be 40-85% of predicted normal value at visit 1.
Patients who had received parenteral depot corticosteroid during the 3 months prior to study or who had an exacerbation of their asthma during the 4 weeks prior to entry requiring additional oral/parenteral steroids or nebulised &agonists were excluded from the study, as were patients with intercurrent respiratory infection, significant seasonal allergy, or any significant disease other than asthma.
STUDY DESIGN AND TREATMENT
The study was performed in accordance with the Declaration of Helsinki and the protocol was approved by the Comite Consultatif de Protection des Personnes dans la Recherche Biomedicale de Lille before the study commenced.
This was a double-blind, randomized, multicentre study with two parallel treatment groups. There was an initial 2-week run-in period during which patients completed diary cards whilst on their standard medication. They were then randomized (in blocks of four at each centre) to receive double-dummy treatment with either: active bambuterol tablets, 10 mg (one-half 20 mg tablet) once daily at bedtime for 7 days increasing to 20 mg (one tablet) at bedtime for the remaining 5 weeks, plus placebo salmeterol p-MDI, 2 puffs morning and evening (12 h apart) for 6 weeks; or active salmeterol p-MD& 50,~g (2 puffs) morning and evening (12 h apart) for 6 weeks, plus placebo bambuterol at bedtime, half a tablet for 1 week and one tablet for the remaining 5 weeks.
Active treatment started with an evening dose at visit 2 and no dose adjustments were permitted during the study. Patients returned to the clinic for visit 3 after 3 weeks and for visit 4 after 6 weeks of active treatment.
Concomitant medication
Concomitant treatment with short-acting inhaled bronchodilators was permitted for rescue therapy during the study, but preferably not within 6 h of PEF measurement (salmeterol was not to be used as a rescue therapy). Regular inhaled or oral therapy with corticosteroids in the doses defined in the inclusion criteria was permitted, as was regular treatment with disodium cromoglycate or nedocromil sodium (inhaled, nasal or ocular), nasal corticosteroids, slow-release and rectal theophylline or antihistamines.
If an exacerbation of asthma occurred during the study, additional treatment with inhaled or nebulised short-acting bronchodilators or parenteral bronchodilators was permitted for up to 4 days, but no longer. If a second exacerbation occurred, the patient was excluded from the study.
No /I-blockers were permitted during the study. Any other medication considered necessary for the patient's welfare was to be given at the investigator's discretion.
CLINICAL AND LABORATORY ASSESSMENT
At the clinic At visit 1 patients were informed about the study and asked to give their written informed consent to participate.
Details of demography (age, sex, height, weight, ethnic group), current medication, duration of asthma and smoking habits were recorded and entry criteria were confirmed. Baseline and post-bronchodilator FEV, (15-30 min after inhalation of terbutaline sulphate 1.0 mg, via Turbuhaler@) were measured and calculated as % of normal predicted. These measurements were to be done between 6 and 72 h after the patient had taken a bronchodilator, depending on the type taken pre-entry (i.e. at least 6 h after a short-acting inhaled &agonist and 72 h after salmeterol). Patients were shown how to use a PEF meter (Vitalographa, Vitalograph Ltd., Bucks, U.K.) and were issued with diary cards for recording of lung function, symptoms and sleep disturbance daily at home. Their pMDI inhalation technique was checked and if there was any doubt about their competence, they were provided with a spacer (Volumatic@, Laboratories Glaxo, Paris, France) for use with the study pMD1.
At visit 2 (end of 2-week run-in period), patients were asked whether they had experienced any adverse events and they completed a questionnaire on nocturnal asthma symptoms.
After 3 weeks of study medication (visit 3), patients returned to the clinic for assessment of compliance, including a check on their pMDI technique, and to record any adverse events.
At the end of the 6-week study period (visit 4) diary cards were collected along with any unused medication, any adverse events were recorded and patients were asked to complete a second questionnaire about nocturnal asthma symptoms.
Af home
Diary cards were completed twice daily. In the morning, PEF (best of three blows, performed no longer than 10 minutes after awakening) and awakening during the night due to asthma (Yes or No) were recorded along with details of rescue bronchodilator use. In the evening, PEF (best of three blows, before medication and, if possible, at least 6 h after the last inhalation of short-acting bronchodilator) and asthma symptoms and tremor during the day (scaled from O-3, where O=no symptoms and 3 =severe symptoms) were recorded along with details of rescue bronchodilator use.
Staatistical analyses
It was calculated that, with a sample size of 50 patients in each treatment group, there was an 80% power (at the 5% significance level) of detecting a true difference of 221 min-' between treatments. The primary efficacy variable was morning PEF change from baseline during treatment period, expressed as absolute value (1 min -'). Mean baseline values were calculated over the last 2 weeks of the run-in period. Regarding the treatment period, for the efficacy variables, mean values were calculated over the last 4 weeks. This rule was adopted because the full dose of bambuterol was given after 1 week of treatment, as recommended. For the tremor variable, mean values were calculated over the whole treatment period in order not to exclude the first days of treatment.
Simple comparisons were performed for categorical data using the chi-square test and for continuous data using either the Student's t-test for normally distributed variables or the Mann-Whitney U-test for variables which were not normally distributed.
Comparisons between treatment groups of FEV, and PEF were performed using the Student's t-test (for absolute values), and the Mann-Whitney U-test (for percentages). The Mann-Whitney U-test was also used for continuous not normally distributed variables and ordinal variables: number of days on study medication, daily dose of medication, nocturnal awakenings, intake of &agonists, symptom scores, symptom-free days and tremor scores. Regarding the primary variable, a multivariate analysis was also performed using the variancelcovariance technique with the PROC GLM of the SAS software (version 6.08, SAS Institute Inc., Cary, NC, U.S.A.).
Results
A total of 117 patients were randomized to study treatments, 57 to receive bambuterol and 60 to receive salmeterol. Their demographic and baseline lung function data are presented in Table 1 . The two treatment groups were similar with respect to age, physical characteristics and intake of inhaled or oral steroids. Both (bambuterol and salmeterol groups, respectively) had similar baseline lung function (64 and 64.6% predicted FEV,) and demonstrated similar mean reversibility to &agonist (11 and 13%). The mean duration of asthma was slightly longer in the bambuterol group (18 years) compared with the salmeterol group (14.8 years), but the numbers of patients on oral steroids were similar (8 and 9 respectively). One patient on bambuterol was taking oral steroids without any concomitant inhaled steroids.
Twenty-one patients discontinued the study prematurely, 10 during bambuterol and 11 during salmeterol treatment, for reasons summarized in Table 2 . As a result, three patients were excluded from the safety and efficacy analyses (one bambuterol, two salmeterol). A further nine patients were excluded from the efficacy analysis for the following reasons: treatment period less than 14 days (seven bambuterol, one salmeterol); one (bambuterol) patient received both active medications. The time to discontinuation tended to be shorter in the bambuterol than in the salmeterol group.
CLINICAL EFFICACY Lung function
Lung function (PEF) data during run-in and active treatment are summarized in Table 3 . In both treatment groups, there were similar increases in morning and evening PEF from run-in to active treatment and when these were compared between the groups, no significant differences were detected (morning PEF, P~0.86; evening PEF, 
Diurnal variation in PEF
Mean percentage fall in overnight PEF was calculated for run-in and active treatment periods. During both active treatments, there was a significant reduction in the overnight fall in PEF compared with run-in from 16.1 to 7.8% for bambuterol (P<O*OOl) and from 13.4 to 6.6% for salmeterol (P<O.OOl), respectively, with no significant difference between the treatment effects (P=O.47).
Nocturnal and dayfime symptoms case), but no significant difference between the treatments (Fig. 1) . Nocturnal symptoms were assessed according to the Daytime symptoms were assessed according to their number of times a patient awoke during the night or early severity and followed a similar pattern to nocturnal morning due to asthma. During the run-in, patients in each symptoms, i.e. there was a significant fall in symptom scores group awoke approximately every other night due to their from the run-in period to active treatment with bambuterol asthma. There was a significant decrease in the number of (P<O.OOl) or salmeterol (P<O*OOl), but no significant difawakenings during each active treatment (PcO.01 in each ference between the treatments (Table 3) 
SAFETY AND TOLERABILITY
Adverse events were reported in 33 out of 56 patients in the bambuterol group and 28 out of 58 patients in the salmeterol group. The most frequent events involved the respiratory system (21 bambuterol, 11 salmeterol). Pharmacologically predictable adverse events were as follows: headache (six bambuterol, two salmeterol); tremor (three bambuterol, three salmeterol); cramps (two bambuterol); and tachycardia and/or palpitation (three bambuterol, one salmeterol). Seven patients were prematurely discontinued from the study due to an asthma exacerbation (two bambuterol, five salmeterol): in four cases (one bambuterol, three salmeterol) asthma exacerbation resulted in hospitalization. In addition, five patients were withdrawn from the study due to adverse events possibly related pharmacologically to the study drugs: four in the bambuterol group (one headache; one insomnia; one mental excitation; one facial flush) and one in the salmeterol group (tremor). Mean tremor scores (SD) from patient diary cards were very low during the run-in period, 0.21 (0.53) in the bambuterol group and 0.31 (0.58) in the salmeterol group respectively. They remained very low during both bambuterol [0.16 (0.34) 
Discussion
The patients in this study were considered to have moderate to severe asthma and had been on combined treatment with bronchodilators and inhaled or oral glucocorticosteroids which was thought to be optimal for their condition. They still complained of troublesome nocturnal symptoms, however. The present results indicate that the bambuterol and salmeterol groups obtained similar benefit from their treatment in terms of improvement in PEF and symptoms and reduction in overnight PEF dipping. As a result, patients had fewer disturbed nights due to their asthma. Although FEV, and reversibility were similar at study entry, mean morning and evening PEF during run-in tended to be lower in the bambuterol than in the salmeterol group. However, this difference did not reach statistical significance. Moreover, a complementary analysis showed that the baseline value of morning PEF had no influence on its change from baseline during treatment. All other parameters reflecting asthma severity, as shown in Tables 1 and 3 , were very similar. Therefore it is unlikely that this random difference in baseline had any effect on the response to therapy.
In patients of this severity, some of whom were on oral steroids in addition to their high-dose inhaled steroid therapy, it is preferable not to increase the steroid intake further. A recent study by Greening et al. (12) has shown that further increases in inhaled steroid therapy may, in any case, be less effective than the addition of a long-acting bronchodilator such as salmeterol. The results of our study confirm the effectiveness of twice-daily salmeterol in more severe asthmatics, but also indicate that similar efficacy can be obtained from a single daily tablet of bambuterol. The dose of bambuterol selected for our study was based on the clear dose-response in bronchodilation obtained in a study with 10 and 20 mg nocte (13) . In more severe asthmatics, 20 mg nocte is thought to be the optimal dose. The dose of salmeterol selected was the standard prescribed dose shown to have a duration of 12 h (10).
The use of P,-agonists for nocturnal symptoms has, in the past, been restricted in some patients due to unwanted tremor effects. Although the controlled-release preparations of terbutaline and salbutamol went some way towards solving this problem, there was room for improvement. Our results indicate that the addition of bambuterol or salmeterol to 'optimal' therapy can improve lung function and provide excellent relief from nocturnal symptoms without producing major tremor. To our knowledge, this is the first large controlled comparison of bambuterol and salmeterol and we conclude that either drug is safe and effective for the control of nocturnal symptoms in moderate to severe asthmatic patients.
